Search

Displaying results 7851 - 7860 of 10000 in total
  1. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.

  2. Drug

    NLX-P101

    go.drugbank.com/drugs/DB05924
    Experimental

    NLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients. … which is overactive in patients with Parkinson’s disease.

  3. Drug

    Pegdinetanib

    go.drugbank.com/drugs/DB05931
    Investigational

    As a result, CT-322 blocks all known ligands for VEGFR-2. … CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis

    Categories: Vascular Endothelial Growth Factor Receptor-2, antagonists & inhibitors
  4. Drug

    MK-4721

    go.drugbank.com/drugs/DB05933
    Investigational

    MK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients

  5. Drug

    CTCE-0214

    go.drugbank.com/drugs/DB05934
    Experimental

    CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood

  6. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  7. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection. … Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.

  8. Drug

    KOS-2187

    go.drugbank.com/drugs/DB05946
    Experimental

    KOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease

    Synonyms: (3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-7,10,12,13-tetrahydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-6-[3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl, -14-phenyl-oxacyclotetradecan-2-one
  9. Drug

    MD-0727

    go.drugbank.com/drugs/DB05948
    Investigational

    MD-0727 is a novel, potent cholesterol absorption inhibitor (CAI) under investigation for the treatment of hypercholesterolemia (high cholesterol.

  10. Drug

    Contulakin-G

    go.drugbank.com/drugs/DB05950
    Experimental

    Contulakin-G is a broad spectrum non-opioid analgesic. It is the synthetic form of a natural peptide extracted from the venom of the Conus Geographus sea snail.